Bioneer Corporation
Bioneer Corporation engages in the biotechnology research products, molecular diagnosis, drugs, and probiotics businesses in South Korea. The company offers PCR and RT-PCR, real-time PCR, RNAi, chemicals, plastic consumables, and buffer solutions; and sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher, electrophoresis, genome-wide functional analys… Read more
Bioneer Corporation (064550) - Net Assets
Latest net assets as of September 2025: ₩229.21 Billion KRW
Based on the latest financial reports, Bioneer Corporation (064550) has net assets worth ₩229.21 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩376.52 Billion) and total liabilities (₩147.32 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩229.21 Billion |
| % of Total Assets | 60.87% |
| Annual Growth Rate | 14.77% |
| 5-Year Change | 55.83% |
| 10-Year Change | 557.06% |
| Growth Volatility | 101.05 |
Bioneer Corporation - Net Assets Trend (2011–2024)
This chart illustrates how Bioneer Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bioneer Corporation (2011–2024)
The table below shows the annual net assets of Bioneer Corporation from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩226.89 Billion | -3.40% |
| 2023-12-31 | ₩234.88 Billion | -0.48% |
| 2022-12-31 | ₩236.00 Billion | +16.23% |
| 2021-12-31 | ₩203.05 Billion | +39.45% |
| 2020-12-31 | ₩145.61 Billion | +375.69% |
| 2019-12-31 | ₩30.61 Billion | -21.49% |
| 2018-12-31 | ₩38.99 Billion | +43.63% |
| 2017-12-31 | ₩27.15 Billion | +3.95% |
| 2016-12-31 | ₩26.11 Billion | -24.37% |
| 2015-12-31 | ₩34.53 Billion | +14.34% |
| 2014-12-31 | ₩30.20 Billion | +2.25% |
| 2013-12-31 | ₩29.54 Billion | -6.00% |
| 2012-12-31 | ₩31.42 Billion | -16.96% |
| 2011-12-31 | ₩37.84 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bioneer Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3111.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩264.41 Billion | 123.60% |
| Total Equity | ₩213.92 Billion | 100.00% |
Bioneer Corporation Competitors by Market Cap
The table below lists competitors of Bioneer Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tonix Pharmaceuticals Holding Corp
NASDAQ:TNXP
|
$176.11 Million |
|
MedinCell S.A
PINK:MDCLF
|
$176.11 Million |
|
Lagardere SCA
PA:MMB
|
$176.13 Million |
|
Kingstone Companies Inc
NASDAQ:KINS
|
$176.13 Million |
|
Ningbo Joy Intelligent Logistics Technology Co.Ltd.
SHE:301198
|
$175.96 Million |
|
CIVEO CORP. DL -01
F:44C1
|
$175.95 Million |
|
Minera Valparaiso S.A.
SN:MINERA
|
$175.94 Million |
|
Fujian Nanwang Environment Protection Scien-Tech Co. Ltd. A
SHE:301355
|
$175.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bioneer Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 223,875,983,960 to 213,917,936,530, a change of -9,958,047,430 (-4.4%).
- Net loss of 20,584,198,230 reduced equity.
- Other factors increased equity by 10,626,150,800.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-20.58 Billion | -9.62% |
| Other Changes | ₩10.63 Billion | +4.97% |
| Total Change | ₩- | -4.45% |
Book Value vs Market Value Analysis
This analysis compares Bioneer Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.46x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 8.02x to 1.46x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1508.06 | ₩12100.00 | x |
| 2017-12-31 | ₩1316.19 | ₩12100.00 | x |
| 2018-12-31 | ₩1890.40 | ₩12100.00 | x |
| 2019-12-31 | ₩1375.01 | ₩12100.00 | x |
| 2020-12-31 | ₩5775.36 | ₩12100.00 | x |
| 2021-12-31 | ₩7866.96 | ₩12100.00 | x |
| 2022-12-31 | ₩9143.73 | ₩12100.00 | x |
| 2023-12-31 | ₩8673.90 | ₩12100.00 | x |
| 2024-12-31 | ₩8288.09 | ₩12100.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bioneer Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.62%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7.00%
- • Asset Turnover: 0.88x
- • Equity Multiplier: 1.55x
- Recent ROE (-9.62%) is above the historical average (-14.21%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -44.90% | -75.95% | 0.27x | 2.23x | ₩-16.58 Billion |
| 2015 | -15.56% | -25.79% | 0.29x | 2.08x | ₩-8.83 Billion |
| 2016 | -55.21% | -66.44% | 0.34x | 2.44x | ₩-17.03 Billion |
| 2017 | -36.38% | -42.44% | 0.40x | 2.16x | ₩-12.59 Billion |
| 2018 | -22.62% | -36.63% | 0.34x | 1.82x | ₩-12.72 Billion |
| 2019 | -25.57% | -21.57% | 0.44x | 2.68x | ₩-10.89 Billion |
| 2020 | 39.76% | 27.97% | 1.08x | 1.31x | ₩43.34 Billion |
| 2021 | 13.38% | 12.14% | 0.85x | 1.29x | ₩6.85 Billion |
| 2022 | 5.12% | 5.53% | 0.73x | 1.27x | ₩-11.52 Billion |
| 2023 | -4.73% | -4.02% | 0.83x | 1.41x | ₩-32.97 Billion |
| 2024 | -9.62% | -7.00% | 0.88x | 1.55x | ₩-41.98 Billion |
Industry Comparison
This section compares Bioneer Corporation's net assets metrics with peer companies in the Biotechnology & Medical Research industry.
Industry Context
- Industry: Biotechnology & Medical Research
- Average net assets among peers: $65,491,230,312
- Average return on equity (ROE) among peers: -1.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bioneer Corporation (064550) | ₩229.21 Billion | -44.90% | 0.64x | $175.97 Million |
| Macrogen Inc (038290) | $118.01 Billion | 2.24% | 0.52x | $99.40 Million |
| Panagene Inc (046210) | $30.94 Billion | 0.00% | 0.90x | $29.96 Million |
| Cell Biotech Co. Ltd (049960) | $52.36 Billion | 19.87% | 0.10x | $43.10 Million |
| MEDIPOST Co. Ltd (078160) | $143.31 Billion | -3.74% | 0.25x | $192.41 Million |
| Biotoxtech Co. Ltd (086040) | $41.14 Billion | 17.29% | 1.21x | $23.35 Million |
| Peptron Inc (087010) | $7.18 Billion | -42.42% | 0.61x | $3.92 Billion |